

Joerg Hasford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7030168/publications.pdf>

Version: 2024-02-01

60
papers

3,875
citations

304743

22
h-index

144013

57
g-index

65
all docs

65
docs citations

65
times ranked

2997
citing authors

#	ARTICLE	IF	CITATIONS
1	A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group. Journal of the National Cancer Institute, 1998, 90, 850-859.	6.3	728
2	Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood, 2011, 118, 686-692.	1.4	413
3	Chronic myeloid leukemia and interferon- γ : a study of complete cytogenetic responders. Blood, 2001, 98, 3074-3081.	1.4	309
4	Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon- γ in Newly Diagnosed Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 1634-1642.	1.6	307
5	Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. Journal of Clinical Oncology, 2014, 32, 415-423.	1.6	271
6	Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood, 2011, 118, 6760-6768.	1.4	254
7	Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 2010, 115, 1880-1885.	1.4	198
8	Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood, 2015, 126, 42-49.	1.4	171
9	Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood, 2007, 109, 4686-4692.	1.4	141
10	Epidemiology of chronic myeloid leukaemia (CML). Best Practice and Research in Clinical Haematology, 2009, 22, 295-302.	1.7	119
11	Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study. Leukemia Research, 2014, 38, 57-64.	0.8	68
12	Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment – a review. Cardiovascular Diabetology, 2009, 8, 18.	6.8	67
13	Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Annals of Hematology, 2015, 94, 2015-2024.	1.8	67
14	Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1167-1176.	2.5	67
15	Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. European Journal of Clinical Pharmacology, 2007, 63, 1055-1061.	1.9	61
16	Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Annals of Hematology, 2014, 93, 71-80.	1.8	60
17	The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia, 2020, 34, 2138-2149.	7.2	55
18	Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial. Diabetologia, 2021, 64, 1079-1092.	6.3	31

#	ARTICLE	IF	CITATIONS
19	Assessing the Safety of Drugs in Pregnancy. <i>Drug Safety</i> , 2000, 22, 169-177.	3.2	28
20	First results from an intensified monitoring system to estimate drug related hospital admissions. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 196-200.	2.4	28
21	The impact of health care settings on survival time of patients with chronic myeloid leukemia. <i>Blood</i> , 2014, 123, 2494-2496.	1.4	27
22	A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotine patch. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 443-447.	1.9	23
23	Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death. <i>Annals of Hematology</i> , 2015, 94, 209-218.	1.8	22
24	Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. <i>Leukemia</i> , 2018, 32, 1222-1228.	7.2	22
25	Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. <i>Annals of Hematology</i> , 2014, 93, 1167-1176.	1.8	21
26	24-Hour blood pressure measurement in antihypertensive drug trials: Data requirements and methods of analysis. <i>Statistics in Medicine</i> , 1992, 11, 2147-2158.	1.6	20
27	Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death. <i>Cancer</i> , 2017, 123, 2467-2471.	4.1	18
28	Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. <i>Haematologica</i> , 2019, 104, 955-962.	3.5	18
29	Redundant trials can be prevented, if the EU clinical trial regulation is applied duly. <i>BMC Medical Ethics</i> , 2020, 21, 107.	2.4	18
30	Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. <i>American Journal of Hematology</i> , 2019, 94, 1236-1243.	4.1	17
31	Drug risk assessment: A case for large trials with lean protocols. <i>Pharmacoepidemiology and Drug Safety</i> , 1994, 3, 321-327.	1.9	14
32	Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1311-1318.	2.5	14
33	Drug use assessment and risk evaluation in pregnancy—the PEGASUS-project. <i>Pharmacoepidemiology and Drug Safety</i> , 1997, 6, S37-S42.	1.9	13
34	The EUTOS CML score aims to support clinical decision-making. <i>Blood</i> , 2012, 119, 2966-2967.	1.4	12
35	Tiotropium Respimat® vs. HandiHaler®: real-life usage and TIOSPIR trial generalizability. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 379-388.	2.4	12
36	The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha. <i>Haematologica</i> , 2005, 90, 335-40.	3.5	12

#	ARTICLE	IF	CITATIONS
37	Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1441-1447.	2.5	11
38	Time Trends of Period Prevalence Rates of Patients with Inhaled Long-Acting Beta-2-Agonists-Containing Prescriptions: A European Comparative Database Study. <i>PLoS ONE</i> , 2015, 10, e0117628.	2.5	11
39	The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry.. <i>Blood</i> , 2009, 114, 4272-4272.	1.4	11
40	Utilisation and Off-Label Prescriptions of Respiratory Drugs in Children. <i>PLoS ONE</i> , 2014, 9, e105110.	2.5	10
41	Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV. <i>Blood</i> , 2008, 112, 333-333.	1.4	10
42	Screening for asymptomatic \hat{I}^2 -cell autoimmunity in young children. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 288-290.	5.6	8
43	Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with \hat{I}^{\pm} -interferon: comments. <i>British Journal of Haematology</i> , 2001, 114, 241-241.	2.5	7
44	Correct use of non-indexed eGFR for drug dosing and renal drug-related problems at hospital admission. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1683-1693.	1.9	7
45	Medical registries represent vital patient interests and should not be dismantled by stricter regulation. <i>Cancer Epidemiology</i> , 2012, 36, 575-578.	1.9	6
46	Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial. <i>BMC Pulmonary Medicine</i> , 2015, 15, 55.	2.0	6
47	A multi-state model approach for prediction in chronic myeloid leukaemia. <i>Annals of Hematology</i> , 2015, 94, 919-927.	1.8	6
48	Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1367-1381.	2.5	5
49	Impact of the COVID-19 pandemic on clinical trials with drugs. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1373-1375.	2.4	5
50	Implementation of the EU clinical trial regulation transforms the ethics committee systems and endangers ethical standards. <i>Journal of Medical Ethics</i> , 2021, 47, e82-e82.	1.8	5
51	Incidence, Comorbidity and Treatment Survey of Chronic Myeloid Leukemia in Germany.. <i>Blood</i> , 2007, 110, 2964-2964.	1.4	4
52	Design and Analysis of Clinical Trials of Compliance. , 0, , 23-40.		3
53	Etiology and Epidemiology of Chronic Myeloid Leukemia. , 2013, , 11-17.		3
54	Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population-based study. <i>European Journal of Haematology</i> , 2019, 103, 362-369.	2.2	3

#	ARTICLE	IF	CITATIONS
55	Implementation of a renal pharmacist consultant service – Information sharing in paper versus digital form. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 838-845.	1.5	3
56	Large Simple Double-Blind Randomized Trials for the Rapid Assessment of the Effectiveness of COVID-19 Vaccines. <i>Journal of Infectious Diseases</i> , 2020, 222, 1571-1572.	4.0	2
57	Regional reporting of adverse drug reactions: a new computer-based network. , 1999, 8, S47-S53.		0
58	Prognostic Scores for Patients with Chronic Myeloid Leukemia Under Particular Consideration of Disease-Specific Death. <i>Hematologic Malignancies</i> , 2016, , 111-128.	0.2	0
59	Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death. <i>Hematologic Malignancies</i> , 2021, , 119-143.	0.2	0
60	The European Leukemia Net CML Registry - Objectives, Achievements and First Results.. <i>Blood</i> , 2006, 108, 4781-4781.	1.4	0